Puma Biotechnology, Inc.
NASDAQ:PBYIBiotechnology
+$0.16 today
- Market cap
- $373.26M
- Beta
- 1.21
- P/E (TTM)
- 15.4
- EPS (TTM)
- $0.48
Volume 0.45M
Average 0.26M
PBYI Total Non-current Assets
All assets not expected to be converted to cash within one year.
Puma Biotechnology, Inc.NASDAQ: PBYI
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets falls 20.8% from a year ago
Total non-current assets stood at $50.44M at the end of Q1 FY2026, down 20.8% from a year earlier and down 5.9% from the prior quarter. Over 3 fiscal years it compounded at -15.2% a year.
Context
- Total non-current assets amounted to 26.2% of total assets at the end of Q1 FY2026, down 6.3 pp from a year earlier.
- Total non-current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -20.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 53.62M USD
- Year-over-year change
- -18.4%
- 4-year CAGR
- -11.3%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 53.62M | -18.4% |
| FY2024 | 2024-12-31 | 65.68M | -11.7% |
| FY2023 | 2023-12-31 | 74.34M | -15.3% |
| FY2022 | 2022-12-31 | 87.78M | +1.4% |
| FY2021 | 2021-12-31 | 86.56M | — |
Total Non-current Assets vs competitors
How PBYI compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -20.8% is the 6th highest of 11, against a peer median of -20.8%.
- Total non-current assets amounts to 26.2% of total assets for PBYI, versus a peer median of 7.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $146.53M USD | +366.3% | +45.4% | 33.5% | |
| Mar 2026 | $50.44M USD | -20.8% | -15.2% | 26.2% | |
| Sep 2026 | $40.8M USD | -12.0% | -9.8% | 3.9% | |
| Mar 2026 | $35.35M USD | -16.8% | -18.2% | 16.2% | |
| Mar 2026 | $24.9M USD | +255.8% | +119.4% | 10.9% | |
| Jun 2026 | $18.07M USD | -24.8% | +69.1% | 2.4% | |
| Mar 2026 | $9.96M USD | -51.6% | -28.2% | 7.5% | |
NBPNovaBridge Biosciences | Dec 2025 | $6.15M USD | -97.7% | -76.0% | 16.5% |
| Mar 2026 | $1.83M USD | -12.7% | -29.0% | 3.7% | |
| Mar 2026 | CA$674K CAD | -44.5% | -15.0% | 8.3% | |
| Mar 2026 | $595K USD | -98.0% | +8.8% | 0.2% | |
| Peer median (excluding PBYI) | — | -20.8% | -12.4% | 7.9% | |
Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 63.13M | 76.2M | 84.59M | 69.22M | 29.64M |
| Short-term Investments | 18.98M | 4.87M | 11.35M | 31.75M | 67.89M |
| Net Receivables | 32.53M | 42.27M | 48.49M | 32.01M | 53.65M |
| Inventory | 7.11M | 4.53M | 7.08M | 8.72M | 5.52M |
| Other Current Assets | 11.43M | 1.95M | 260K | 3.7M | 4M |
| Total Current Assets | 140.02M | 134.28M | 156.19M | 147.66M | 162.69M |
| Property, Plant & Equipment (Net) | 15.77M | 12.51M | 8.65M | 5.09M | 5.56M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 66.13M | 70.61M | 60.87M | 51.13M | 41.39M |
| Long-term Investments | 0 | 0 | 2.09M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 7.08M | 3.83M |
| Other Non-current Assets | 4.67M | 4.66M | 2.73M | 2.38M | 2.83M |
| Total Non-current Assets | 86.56M | 87.78M | 74.34M | 65.68M | 53.62M |
| Total Assets | 226.59M | 222.06M | 230.53M | 213.33M | 216.3M |
| Account Payables | 11.17M | 6.44M | 6.89M | 5.51M | 5.06M |
| Short-term Debt | 0 | 0 | 34M | 45.33M | 22.52M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 11.22M | 13.34M | 43.42M | 15.18M | 16.5M |
| Total Current Liabilities | 109.59M | 77.48M | 99.38M | 96.11M | 81.25M |
| Long-term Debt | 97.09M | 98.31M | 65.66M | 21.72M | 4.71M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 6.38M | 12.83M | 5.01M | 1.88M | 0 |
| Total Non-current Liabilities | 119.45M | 122.97M | 77.7M | 25.1M | 4.71M |
| Total Liabilities | 229.03M | 200.45M | 177.09M | 121.21M | 85.96M |
| Common Stock | 4K | 5K | 5K | 5K | 5K |
| Retained Earnings | (1.37B) | (1.37B) | (1.35B) | (1.31B) | (1.28B) |
| Accumulated OCI | (2K) | 0 | (4K) | 6K | 36K |
| Other Stockholders Equity | 0 | (0) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (2.45M) | 21.61M | 53.44M | 92.13M | 130.34M |
| Total Debt | 116.64M | 114.28M | 111.49M | 74.08M | 28.55M |
| Net Debt | 53.51M | 38.08M | 26.91M | 4.86M | (1.09M) |
Puma Biotechnology, Inc.
NASDAQ:PBYI
Intrinsic Alpha fair value
Locked
Current Price
$7.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.